By Billy Candra 
Stanford Medicine researchers have unveiled a groundbreaking classification system for breast cancer, bundling existing subgroups into three primary categories based on fundamental structural variations within their DNA. These variations, which include repeats or amplifications of cancer-associated genes (oncogenes) on chromosomes and the presence of small DNA circles known as extrachromosomal DNA (ecDNA), are not merely incidental. Instead, they are established early in the cancer’s development and persist as the disease progresses and metastasizes. This robust new framework, published January 8 in Nature, promises to revolutionize diagnostic approaches, inform therapeutic decisions, and offer a clearer path to identifying patients who could benefit most from aggressive early intervention versus those for whom certain treatments might be safely deferred.
Unlocking Breast Cancer’s Genomic Secrets
The findings, spearheaded by Christina Curtis, PhD, the RZ Cao Professor and a professor of oncology, genetics, and biomedical data science at Stanford Medicine, represent a significant leap in understanding the molecular underpinnings of breast cancer. Dr. Curtis, the senior author of the research, emphasized the profound implications of their discovery: "My lab has had a long-standing interest in understanding how aggressive breast tumors arise, why they are resistant to therapy and why they are prone to recur in distant organs. This research shows that breast tumors develop key structural variants that set the tumor on its course very early in its development. In short, some are born to be bad. It emphasizes the importance of robust biomarkers and of intervening early in the course of the disease." This perspective underscores a critical shift from reactive treatment to proactive, precision-guided strategies.
The study’s lead authors include former postdoctoral scholar Kathleen Houlahan, PhD, postdoctoral scholar Lise Mangiante, PhD, former research assistant Cristina Sotomayor-Vivas, and graduate student Alvina Adimoelja, highlighting a collaborative effort that has culminated in a new understanding of tumor evolution. The research was supported by critical funding from the National Institutes of Health and the Breast Cancer Research Foundation, underscoring its potential impact on public health.
A Paradigm Shift in Classification
For decades, breast cancers have been broadly categorized based on the presence or absence of specific protein receptors: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). This traditional classification system divides breast cancers into three main types:
- Hormone-receptor positive (HR+): These tumors express ER and/or PR, making up the majority of breast cancer cases (approximately 70-80%). They are often treated with hormone therapies that aim to lower estrogen production, block estrogen binding, or degrade estrogen receptors. While generally having a better prognosis than other types, a significant subset can recur years, even decades, after initial treatment.
- HER2-positive (HER2+): Constituting about 15-20% of all cases, these cancers overexpress the HER2 protein. Historically aggressive, the development of targeted therapies like trastuzumab (Herceptin) has dramatically improved outcomes for these patients, transforming a previously challenging diagnosis into one with often manageable long-term prognoses.
- Triple-negative breast cancer (TNBC): Accounting for roughly 10-15% of newly diagnosed cases, TNBC lacks expression of ER, PR, and HER2. These cancers are notoriously aggressive, challenging to treat successfully, and tend to recur earlier than other types. Treatment typically relies on chemotherapy, surgery, and radiation, with limited targeted options until recently.
While these classifications have guided treatment for years, they often don’t fully capture the complexity of individual tumors or their long-term behavior. The new Stanford research aims to provide a deeper, more accurate layer of classification by focusing on the fundamental genomic architecture.
The Journey to Deeper Understanding: From Receptors to Genes
Dr. Curtis, who also directs artificial intelligence and cancer genomics at the Stanford Cancer Institute, has been at the forefront of breast cancer evolution research for over a decade. Her work exemplifies a methodical, progressive approach to unraveling the disease’s intricacies.
A. The Molecular Revolution: Curtis Lab’s Earlier Insights (2012)
The journey toward this latest breakthrough began in 2012 when Dr. Curtis and her colleagues utilized advanced machine-learning techniques to analyze DNA and RNA sequences from patients’ healthy cells and their breast tumors. This molecular snapshot allowed them to identify not just genetic alterations but also their impact on gene expression. The study was a watershed moment, identifying 11 clinically significant subgroups—a significant expansion beyond the receptor-based classification. While these subgroups clearly showed varied prognoses, the immediate practical application for guiding patient care remained a challenge. This initial work, however, laid the groundwork for understanding that breast cancer was far more heterogeneous at a molecular level than previously understood.
B. Unmasking Long-Term Recurrence Risks (2019)
A subsequent study, involving an extensive cohort of 75,000 individuals with estrogen-receptor positive breast cancer, highlighted a persistent clinical challenge: even after five years of hormone therapy, recurrences continued, even in patients initially classified as low-risk. This prompted Dr. Curtis and her team to investigate whether their previously defined molecular subgroups could better delineate this elusive risk.
Their 2019 research revealed a critical insight: overlaying the traditional receptor status with their molecular subgroup classification could powerfully predict which HR+ tumors were prone to recurring long after initial diagnosis and treatment. Specifically, four of the eight estrogen-receptor positive subgroups demonstrated a significantly higher likelihood of recurrence, even 10 or 20 years post-diagnosis. When these four high-risk groups were combined, a staggering one-quarter of women with hormone-receptor positive, HER2-negative breast tumors faced nearly a 50% chance of recurrence decades after initial diagnosis. This elevated risk was comparable to that seen in HER2-positive breast cancers before the advent of trastuzumab, underscoring the severity of this overlooked challenge.
Furthermore, this refined approach could also identify triple-negative tumor patients who were unlikely to experience recurrence beyond five years, contrasting them with those who were more susceptible. Such patient stratification is invaluable, allowing clinicians to pinpoint individuals who might require more aggressive early intervention or intensive long-term monitoring, while potentially sparing others from unnecessary harsh treatments. Despite these advances, the precise underlying drivers of these subgroup differences remained largely enigmatic.
Delving into Genomic Architecture: The Three Main Groups (2024)
To address the remaining ambiguities, Dr. Curtis and her team decided to "take a step back," as she described it. Their goal was to move beyond simply identifying patterns to understanding the fundamental genomic processes driving these differences. "Each of the four higher risk subgroups has copy number events — duplications or amplifications of specific oncogenes involving different regions of the genome. These patterns of genomic copy number change were similar to that seen in HER2-positive disease. If we look at these tumors in an unbiased way and deconstruct these different types of mutations, what could we learn about their processes that give rise to these characteristic events? Would we discover something different?"
Their latest research meticulously assessed the genomic architecture—the complete set of mutations and structural variations in a cancer cell’s DNA—from nearly 2,000 breast cancers. This comprehensive analysis included a spectrum of disease stages, from ductal carcinoma in situ (stage 0) to advanced metastatic disease (stage 4). The detailed examination revealed that tumors could be robustly categorized into three distinct groups based on fundamental genomic oddities.
A. Complex Amplifications and Extrachromosomal DNA (ecDNA): The Aggressive Signature
The research found that the high-risk hormone-receptor positive subgroups strongly overlapped with the HER2-positive subgroup in terms of genomic features. Both shared complex but localized amplifications of cancer-associated genes (oncogenes). Critically, these aggressive tumors were also characterized by the presence of small, circular DNA structures known as extrachromosomal DNA (ecDNA), which were "chock-full of oncogenes."
- What is ecDNA? Unlike DNA on chromosomes, ecDNA exists as untethered circles within the cell nucleus. Recent studies have increasingly implicated ecDNAs as potent drivers of cancer growth, evolution, and drug resistance. They can carry multiple copies of oncogenes, enabling rapid gene amplification and expression. Crucially, ecDNAs often ignore normal cellular regulatory mechanisms, allowing cancer cells to quickly adapt and proliferate. This finding highlights a fundamental shared mechanism of aggression between distinct clinical subtypes. "Here we have two different molecular subtypes, which we treat differently in the clinic but that strongly overlap in their patterns of chromosomal instability," Dr. Curtis noted.
B. Global Instability and DNA Repair Deficiencies: The Scarred Genome
Triple-negative tumors, long considered the most aggressive, were found to possess globally unstable genomes. This instability manifested as widespread alterations across the genome, rather than localized amplifications. A significant subset of these globally unstable tumors also exhibited signs of being deficient in their ability to repair DNA damage. This deficiency contributes to the accumulation of mutations and genomic chaos. Dr. Curtis described this phenomenon vividly: "The whole genome shows scars. It’s not limited to particular oncogenes." This pervasive genomic damage and impaired repair mechanism present a unique vulnerability.
C. Stable Genomes: The Lower Risk Profile
In stark contrast, the more "garden-variety" hormone-receptor positive, HER2-negative breast cancers—those associated with typical, lower risks of recurrence—were characterized by relatively stable genomes. These tumors exhibit fewer large-scale structural variations, suggesting a slower, less aggressive evolutionary path.
A crucial aspect of these findings is that these defining structural variations were observed in the earliest stages of the disease (ductal carcinoma in situ) and were consistently maintained as the tumors grew and spread throughout the body. Furthermore, these genomic architectural differences correlated directly with how immune cells infiltrated and responded to the tumor, opening avenues for immunotherapeutic strategies.
Implications for Precision Medicine and Targeted Therapies
Understanding the foundational importance of these structural variations and genomic architecture on cancer development offers profound implications for future therapeutic strategies. This new classification system moves beyond simply describing tumors to explaining why they behave the way they do, pointing directly to potential vulnerabilities.
- Targeting DNA Repair Deficiencies: The researchers speculate that existing drugs designed to target impaired DNA repair pathways, such as PARP inhibitors (commonly used in patients with BRCA1 and BRCA2 mutations leading to inherited forms of breast cancer), might also benefit the approximately 13% of people with DNA repair-deficient, estrogen-receptor positive breast cancers. This expands the potential applicability of established therapies to a broader patient population based on a deeper genomic understanding.
- Attacking ecDNA and Focal Amplifications: Tumors that rely on focal amplifications and ecDNA for their aggressive growth might be vulnerable to compounds specifically designed to target the drivers within these structures or to address the "replication stress" that arises from their uncontrolled proliferation. Developing drugs that disrupt ecDNA formation or function could be a game-changer for these highly aggressive subtypes.
- Intervening Early: The fact that these "catastrophic mutational events" occur decades before diagnosis emphasizes opportunities for earlier interventions. This could involve enhanced screening for high-risk individuals, chemoprevention strategies, or even pre-emptive treatments based on robust genomic biomarkers.
- Patient Stratification and Treatment De-escalation: The ability to differentiate between truly aggressive tumors and those with a more indolent course could lead to more nuanced treatment plans. Patients identified with lower-risk genomic profiles might safely bypass harsher chemotherapy regimens, reducing side effects and improving quality of life without compromising outcomes. Conversely, those with high-risk genomic signatures could receive intensified, targeted treatments from the outset, potentially preventing recurrence.
"Despite the complexity of their genomes, there are constraints and only so many evolutionary paths for a tumor to follow. We now have an understanding of how and when these complex alterations arise and their accompanying vulnerabilities," Dr. Curtis concluded. This sentiment reflects a paradigm shift from a fragmented view of cancer to one that recognizes underlying genomic principles dictating tumor behavior and guiding therapeutic interventions.
The Road Ahead
This research represents a significant stride toward fully personalized breast cancer treatment. By providing a more accurate and predictive classification system, it empowers physicians with better tools to make informed decisions. The integration of artificial intelligence and advanced genomic sequencing continues to drive this progress, transforming our understanding of cancer from a disease of organs to a disease of the genome. As these findings move from the laboratory to clinical practice, they hold immense promise for improving patient outcomes, reducing unnecessary treatments, and ultimately saving lives. Christina Curtis, a member of Bio-X and of the Stanford Cancer Institute and a Chan Zuckerberg Biohub investigator, continues to lead the charge in this vital area of cancer research.
